Prespecified secondary analysis of the phase 3 VALOR trial (241 adults with dermatomyositis): once-daily brepocitinib 30 mg beat placebo on skin activity (mean CDASI-A change −6.4 vs −3.5) and meaningful response (33.3% vs 17.7%) from week 4 to week 52.
Secondary analysisn = 241
Mangold et al. Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial